OncoMatch/Clinical Trials/NCT07032129
Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma
Is NCT07032129 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies BCMA/GPRC5D CAR-T cells for multiple myeloma.
Treatment: BCMA/GPRC5D CAR-T cells — This is an open, single-arm, clinical study to evaluate the efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) targeting BCMA or GPRC5D or both sequentially in the treatment of Relapsed/ Refractory Multiple myeloma
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Prior therapy
Must have received: standard treatment
Subjects with recurrent/refractory Multiple Myeloma who have failed standard treatment or lack effective treatment
Cannot have received: CAR-T cell therapy
Patients who received CAR-T therapy or other gene-modified cell therapy before screening
Cannot have received: gene-modified cell therapy
Patients who received CAR-T therapy or other gene-modified cell therapy before screening
Lab requirements
Kidney function
Creatinine ≤1.5×ULN
Liver function
Total bilirubin ≤2×ULN; ALT and AST≤2.5 x ULN; ALT and AST abnormalities due to disease, such as liver infiltration or bile duct obstruction, were determined to be less than 5×ULN. If Gilbert syndrome is diagnosed, the total bilirubin index can be relaxed to ≤3.0×ULN and the direct bilirubin ≤1.5×ULN.
Cardiac function
Electrocardiogram showed no clinically significant abnormal bands; Blood oxygen saturation >91% in non-oxygen state
Liver and kidney function, cardiopulmonary function meet the following requirements: Creatinine ≤1.5×ULN; (2) Electrocardiogram showed no clinically significant abnormal bands; Blood oxygen saturation >91% in non-oxygen state; Total bilirubin ≤2×ULN; ALT and AST≤2.5 x ULN; ALT and AST abnormalities due to disease, such as liver infiltration or bile duct obstruction, were determined to be less than 5×ULN. If Gilbert syndrome is diagnosed, the total bilirubin index can be relaxed to ≤3.0×ULN and the direct bilirubin ≤1.5×ULN.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify